Knowledge Distillery

The objective of this study was to descriptive analysis of COVID-19 infection in patients with multiple sclerosis (MS) receiving fingolimod or…

At present, delta variant is estimated to have caused more than 99% of COVID-19 infections worldwide; however, a new variant of concern, omicron…

The objective of this test negative case-control study was to evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and…

To estimate the growth of the Omicron variant of concern and its immune escape characteristics, the authors analysed data from all PCR-confirmed…

The Omicron (B.1.1.529) variant of SARS-CoV-2 (severe acute respiratory syndrome coronavirus) was only recently detected in southern Africa, but its…

The emergence of Omicron (Pango lineage B.1.1.529), first identified in Botswana and South Africa, may compromise vaccine effectiveness and lead to…

The Delta variant is now the predominant circulating SARS-CoV-2 strain worldwide. Severity of illness in persons infected with the SARS-CoV-2 Delta…

Identifying and testing individuals likely to have SARS-CoV-2 is critical for infection control, including post-vaccination. Vaccination is a major…

Thrombosis with thrombocytopenia, or thrombocytopenia on its own, have been reported after COVID-19 vaccines. In this article the authors assessed the…

Heterologous COVID-19 vaccination regimens combining vector- and mRNA-based vaccines are already administered, but data on solicited adverse…

Reports suggest that COVID-19 vaccine effectiveness is decreasing, but whether this reflects waning or new SARS-CoV-2 variants—especially delta…

After promising initial results from the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) to persons…